Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02. Results of Operations and Financial
Condition.

On May9, 2017, Monogram Residential Trust,Inc. (the Company,)
issued a press release and supplemental information announcing
its financial results for the quarter ended March31, 2017. The
full text of the press release and the supplemental information
are furnished as Exhibit99.1 and Exhibit99.2, respectively.
Additionally, the Company has posted a copy of the press release
and the supplemental information on its website at
www.monogramres.com.

The information in this Item 2.02 of this Current Report on
Form8-K and the attached Exhibit99.1 and Exhibit99.2 are
furnished to Item 2.02 of Form8-K and shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall the information be deemed
incorporated by reference in any filing under the Securities Act
of 1934, as amended, or the Exchange Act.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits:

ExhibitNo.

Description

99.1

Press Release, dated May9, 2017

99.2

Supplemental Information for the quarter ended March31,
2017


About Inc. (NASDAQ:INCR)

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

Inc. (NASDAQ:INCR) Recent Trading Information

Inc. (NASDAQ:INCR) closed its last trading session up +0.90 at 43.65 with 1,731,087 shares trading hands.

An ad to help with our costs